JEANNY RILEY: Open Payments
NPI 1528733425 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,853 in 96 payments from 22 companies in 2025. Trend: 2023 $1,695 · 2024 $2,449 · 2025 $1,853
Food & beverage: $1,853
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $244 |
| ABBVIE INC. | 15 | $238 |
| GENZYME CORPORATION | 7 | $156 |
| Ardelyx, Inc. | 7 | $145 |
| Madrigal Pharmaceuticals | 7 | $135 |
| Ipsen Biopharmaceuticals, Inc | 6 | $121 |
| Lilly USA, LLC | 6 | $109 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $107 |
| Aimmune Therapeutics, Inc. | 6 | $101 |
| QOL Medical, LLC | 4 | $100 |
Products named: ENTYVIO, DUPIXENT, IBSRELA, REZDIFFRA, IQIRVO, OMVOH, RINVOQ, Sucraid.
Industry payments across AL — which companies pay providers there.
